Literature DB >> 21060000

Hypertensive hypertrophied myocardium is vulnerable to infarction and refractory to erythropoietin-induced protection.

Toshiyuki Yano1, Takayuki Miki, Masaya Tanno, Atsushi Kuno, Takahito Itoh, Akifumi Takada, Tatsuya Sato, Hidemichi Kouzu, Kazuaki Shimamoto, Tetsuji Miura.   

Abstract

The objective of this study was to examine the hypothesis that hypertensive hypertrophy is vulnerable to infarction and defective in cytoprotective mechanisms by modification of intracellular signaling and mitochondrial proteins. Myocardial infarction was induced by 20-minute coronary occlusion/reperfusion in spontaneously hypertensive stroke-prone rats (SHR-SPs) and their controls (Wistar-Kyoto rats [WKYs]). Infarct size expressed as a percentage of area-at-risk was larger by 29% in SHR-SPs than in WKYs. Pretreatment with erythropoietin (EPO) significantly limited infarct size in WKYs but not in SHR-SPs. Ca(2+) retention capacity of mitochondria, an index of the threshold for opening of the mitochondrial permeability transition pore, on reperfusion was reduced in SHR-SPs compared with that in WKYs. Suppression of reactive oxygen species by N-(2-mercaptopropionyl)-glycine increased Ca(2+) retention capacity after reperfusion and limited infarct size in SHR-SPs to levels in WKYs. EPO induced phosphorylation of Akt, extracellular signal-related kinase, and glycogen synthase kinase-3β in the myocardium in both WKYs and SHR-SPs. EPO enhanced interaction of phospho-glycogen synthase kinase-3β and adenine nucleotide translocase on reperfusion in WKYs, although such an effect of EPO was not detected in SHR-SPs. The results suggest that enhanced opening of mitochondrial permeability transition pores by reactive oxygen species and modification of the signal downstream of phospho-glycogen synthase kinase-3β in the mitochondria underlie the increased vulnerability to infarction and the lack of anti-infarct tolerance by EPO, respectively, in hypertensive hypertrophied hearts.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21060000     DOI: 10.1161/HYPERTENSIONAHA.110.158469

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  15 in total

1.  Translocation of glycogen synthase kinase-3β (GSK-3β), a trigger of permeability transition, is kinase activity-dependent and mediated by interaction with voltage-dependent anion channel 2 (VDAC2).

Authors:  Masaya Tanno; Atsushi Kuno; Satoko Ishikawa; Takayuki Miki; Hidemichi Kouzu; Toshiyuki Yano; Hiromichi Murase; Toshiyuki Tobisawa; Makoto Ogasawara; Yoshiyuki Horio; Tetsuji Miura
Journal:  J Biol Chem       Date:  2014-09-03       Impact factor: 5.157

2.  CD36 overexpression predisposes to arrhythmias but reduces infarct size in spontaneously hypertensive rats: gene expression profile analysis.

Authors:  Jan Neckář; Jan Šilhavy; Václav Zídek; Vladimír Landa; Petr Mlejnek; Miroslava Šimáková; J G Seidman; Christine Seidman; Ludmila Kazdová; Martina Klevstig; František Novák; Marek Vecka; František Papoušek; Josef Houštěk; Zdeněk Drahota; Theodore W Kurtz; František Kolář; Michal Pravenec
Journal:  Physiol Genomics       Date:  2011-11-29       Impact factor: 3.107

Review 3.  Enhancing Mitochondrial Health to Treat Hypertension.

Authors:  Alfonso Eirin; Amir Lerman; Lilach O Lerman
Journal:  Curr Hypertens Rep       Date:  2018-08-17       Impact factor: 5.369

Review 4.  Role of Erythropoiesis-Stimulating Agents in Cardiovascular Protection in CKD Patients: Reappraisal of Their Impact and Mechanisms.

Authors:  Tetsuji Miura; Tatsuya Sato; Toshiyuki Yano; Akira Takaguri; Takayuki Miki; Noritsugu Tohse; Keitaro Nishizawa
Journal:  Cardiovasc Drugs Ther       Date:  2022-02-12       Impact factor: 3.727

5.  Does p53 Inhibition Suppress Myocardial Ischemia-Reperfusion Injury?

Authors:  Toshiyuki Yano; Koki Abe; Masaya Tanno; Takayuki Miki; Atsushi Kuno; Tetsuji Miura; Charles Steenbergen
Journal:  J Cardiovasc Pharmacol Ther       Date:  2018-03-19       Impact factor: 2.457

6.  Pivotal role of mTORC2 and involvement of ribosomal protein S6 in cardioprotective signaling.

Authors:  Toshiyuki Yano; Marcella Ferlito; Angel Aponte; Atsushi Kuno; Tetsuji Miura; Elizabeth Murphy; Charles Steenbergen
Journal:  Circ Res       Date:  2014-02-20       Impact factor: 17.367

7.  Myocardial infarction: cardioprotection by erythropoietin.

Authors:  Mark I Talan; Roberto Latini
Journal:  Methods Mol Biol       Date:  2013

8.  Cardioprotection in the aging, diabetic heart: the loss of protective Akt signalling.

Authors:  Hannah J Whittington; Idris Harding; Clemency I M Stephenson; Robert Bell; Derek J Hausenloy; Mihaela M Mocanu; Derek M Yellon
Journal:  Cardiovasc Res       Date:  2013-05-30       Impact factor: 10.787

9.  Accelerated recovery of mitochondrial membrane potential by GSK-3β inactivation affords cardiomyocytes protection from oxidant-induced necrosis.

Authors:  Daisuke Sunaga; Masaya Tanno; Atsushi Kuno; Satoko Ishikawa; Makoto Ogasawara; Toshiyuki Yano; Takayuki Miki; Tetsuji Miura
Journal:  PLoS One       Date:  2014-11-12       Impact factor: 3.240

10.  Gsk-3β inhibitors mimic the cardioprotection mediated by ischemic pre- and postconditioning in hypertensive rats.

Authors:  Luisa F González Arbeláez; Ignacio A Pérez Núñez; Susana M Mosca
Journal:  Biomed Res Int       Date:  2013-10-30       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.